drugset
drugset / Trial / NCT02172170

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 10773 in Healthy Male Subjects

NCT02172170 ↗

Phase 1 Completed 72 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of single rising oral doses of BI 10773 to healthy male subjects.

Timeline

Start
2007-01
Primary completion
2007-03
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 0.5 mg Oral
Subject Empagliflozin Small molecule 800 mg Oral

Indications

No indication recorded.